Reset filters
Publication Types
13 November 2024

Webinar presentations: The PAH microenvironment: lessons learned from tumor microenvironment mechano-induced cell metabolism changes; Identification of arterial and venous morphologic markers in pulmonary arterial hypertension using CT imaging; The keto diet as treatment for pulmonary hypertension associated with obesity; Endothelial transdifferential from exacerbated inflammatory signaling in BMP9 in lung endothelium; The role of pericytes in the pathophysiology of pulmonary arterial hypertension

Members Only
9 October 2024

Webinar presentations: Cellular mechosignaling in pulmonary arterial hypertension; Sex differences in pulmonary arterial hypertension randomized clinical trials; Precapillary pulmonary hypertension and death from COVID-19; Estradiol and estrogen receptor protection of right ventricular function – role of apelin; Prostacyclin reverses right ventricular hypertrophy and dysfunction in severe PAH; Pulmonary vascular complications of heart failure with preserved ejection fraction

Members Only
3 September 2024

Webinar presentations: Autophagy and BMPR2 receptor degradation as the cause of PAH; BMPR1A promotes ID2-ZEB1 interaction to suppress endothelial to mesenchymal transition in PAH; Cardiovascular and pulmonary phenotypes for single and double knockout mice deficient in BMP9 and BMP10; BMPR2 – When and where the animal models match patient disease

Members Only
10 July 2024

Webinar presentations: Autoantibodies as the cause of PAH; Prevalence and effect of myelofibrosis on PAH; Mast cells as the cause of pulmonary vascular remodelling in PAH; B-cell depletion with rituximab for the treatment of systemic sclerosis-associated PH; Emergency myelopoiesis contributes to immune cell exhaustion in pulmonary vascular remodelling

Members Only
14 June 2024

Webinar presentations: Therapeutic efficacy and mechanisms of Drpitor1a in PAH; SNPs for sirtuin3 and uncoupling protein2 are causal of PAH and diabetes disease severity; Mitochondrial control of metabolic, angiogenic, and hematopoietic function in PH onset and progression; Heteroplasmy of wild-type mitochondrial DNA variants causes metabolic heart disease with PH.

Members Only
11 April 2024

Webinar presentations: Update on the Human Lung RNAseq Atlas, Nathan Salomonis, USA; Unsupervised transcriptomic profiling of whole blood shows biologic heterogeneity in iPAH, Allan Lawrie, England; Cellular landscape atlas of pulmonary endarterectomy tissue using single cell RNAseq, Peiran Yang, China; Single cell RNAseq identifies cellular abnormalities in rodent models of PH, Jason Hong, USA.

Members Only
15 February 2024

Webinar presentations: Clinical challenges in developing drug therapies for children with PH, Challenges related to drug approval for children with PH – regulatory perspective, Challenges facing pharmaceuticals in drug development for paediatric PH, Utility of paediatric registries for the characterization of pulmonary hypertensive phenotypes.

Members Only
11 January 2024

Webinar presentations: ADVANCE Trial – Ralinepag – prostacyclin receptor agonist, Fernando Torres; Sotatercept phase 2 and phase 3 trials, Marc Humbert; TORREY Trial – Inhaled seralutinib (PDGFR, CSFIR, c-Kit inhibitor), Robert Frantz; VIPAH-PRN Trial – Vardenafil inhaled phosphodiesterase type-5 inhibitor powder, Veronica Franco

Members Only